Archive

17 Aug Risk of Acute Kidney Injury with concomitant use of Fluoroquinolones and Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers

In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the below listed companies would like to inform you of a risk of acute kidney injury (AKI) in patients treated concomitantly with ACEIs / Angiotensin Receptor blockers (ARBs) and fluoroquinolones....

17 Aug Risk of Acute Kidney Injury with concomitant use of Fluoroquinolones and Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers

In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the below listed companies would like to inform you of a risk of acute kidney injury (AKI) in patients treated concomitantly with Angiotensin Converting Enzyme Inhibitors (ACEIs) Angiotensin receptor blockers (ARBs) and fluoroquinolones....

17 Aug Risk of Acute Kidney Injury with concomitant use of Fluoroquinolones and Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers

In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the below listed companies would like to inform you of a risk of acute kidney injury (AKI) in patients treated concomitantly with ACEls / Angiotensin receptor blockers (ARBs) and fluoroquinolones. ...

17 Aug Risk of Acute Kidney Injury with concomitant use of Fluoroquinolones and Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers – 1 August 2019

In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the below listed companies would like to inform you of a risk of acute kidney injury (AKI) in patients treated concomitantly with Angiotensin-converting enzyme inhibitors (ACEls) / Angiotensin receptor blockers (ARBs) and fluoroquinolones.

Date updated

17 Aug Increased risk of thrombo-embolic events in patients with anti-phopholipid syndrome (APS) treated with Pradaxa

Notification of an important new warning with treatment of patients with anti phospholipid syndrome (APS) and the use Pradaxa: Increased risk of thrombo-embolic events ...

17 Aug Increased risk of thrombo-embolic events in patients with anti-phopholipid syndrome (APS) treated with Xarelto

Important safety information on the treatment of patients with antiphospholipid syndrome (APS) and the use of rivaroxaban (Xarelto®) Possible increased risk for recurrent thrombotic events ...

17 Aug Increased risk of thrombo-embolic events in patients with anti-phopholipid syndrome (APS) treated with Eliquis

Pfizer Laboratories (Pty) Ltd, in agreement with South African Health Products Regulatory Authority (SAHPRA), would like to inform you of the following changes to the Professional Information of Eliquis (apixaban). ...

17 Aug DHCPL for ACE-inhibitor/Angiotensin receptor blocker containing medicines

In collaboration with the South African Health Products Regulatory Authority (SAHPRA), Novartis SA (Pty) Ltd would like to inform you of a risk of acute kidney injury (AKI) in patients treated concomitantly with Angiotensin Converting Enzyme Inhibitors (ACEIs) /Angiotensin receptor blockers (ARBs) and fluoroquinolones. ...

17 Aug Fluoroquinolones: risk of mitral and aortic regurgitation associated with the use of oral and injectable fluoroquinolones

In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the companies listed below would like to inform you about the risk of mitral and aortic regurgitation that should be taken into consideration when prescribing oral fluoroquinolone antibiotics. ...

17 Aug Sandoz and Novartis: Warning about small increased risk of oral clefts following use in the first 12 weeks of pregnancy

In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the below listed companies would like to inform you of an increased risk of cleft lip and/or cleft palate following the use of ZOFRAN® (ondansetron) during the first 12 weeks of pregnancy. ...